The US Department of Health and Human Services (HHS) has recommended that cannabis be reclassified from Schedule I to the less restrictive Schedule III within the Controlled Substance Act.
A significant minority of medical cannabis patients go on to develop cannabis use disorder (CUD), according to a new study. This proportion, however, is still lower than the proportion of recreational consumers with CUD.
Cannabis products in Oregon no longer have to be tested for Aspergillus fungi following a suspension order from the Oregon Court of Appeals.
State regulators in Colorado have issued another health and safety notice after “potentially unsafe levels” of total yeast and mold was found in a batch of cannabis flower.
Cannabis and hallucinogens are more popular than ever in the US, according to an ongoing National Institutes of Health (NIH) survey.
The Missouri Division of Cannabis Regulation has recalled a whopping 62,799 products that weren’t compliantly tracked in the state’s digital trace and trace system.
HHC products are still being sold in states without legal recreational cannabis access, and demand for them is growing.